Therapy options in cutaneous T-cell lymphoma

References

• Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am. J. Public Health 89, 1240–1244 (1999).
   PubMed Web of Science ®Google Scholar
• Bunn P, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treatment Reports. 63, 725–728 (1979).
   PubMedGoogle Scholar
• Kim YH, Hoppe RT. Mycosis fungoides and the sezary syndrome. Semin. Onca 26, 276–289 (1999).
   PubMedGoogle Scholar
• Foss FM, Sausville EA. Prognosis and staging of cutaneous T-cell Lymphoma. Hematot Oncol. Clin. N Am. 9, 1011–1019 (1995).
   PubMedGoogle Scholar
• Kim YH, Jensen RA, Watanabe GL et al. Clinical stage la (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch. Dermatol. 132, 1309–1313 (1996).
   PubMed Web of Science ®Google Scholar
• Kim YH, Chow S, Varghese A et al. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch. Dermatol. 135, 26–32 (1999).
   Google Scholar
• Zackheim HS, Amin S, Mohammed KS et aZ Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival
   Google Scholar
• •• in 489 patients.' Am. Acad. Dermatol. 40, 418–425 (1999).
   Google Scholar
• Rosenberg S. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat. Rep. 61, 1023 (1977).
   PubMedGoogle Scholar
• Muche JM, Lukowsky A, Asadullah K, Gellrich S, Sten-y W Demonstration of frequent occurrence of clonal T-cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood 90(4), 1636–1642 (1997).
   PubMedGoogle Scholar
• ••Establishes the presence of peripheralblood involvement even in patients with limited early-stage disease.
   Google Scholar
• Jackow CM, Gather JC, Hearne V et al. Association of erythrodermic cutaneous T-een lymphoma, superantigen-positive Staphylococcus aureus and oligoclonal T-cell receptor V-13 gene expansion. Blood 89, 32–40 (1997).
   PubMed Web of Science ®Google Scholar
• ••Suggests that infection, especially withStaphylococcus aureus, may play a role in stimulating clonal expansion and erythrodertnic manifestations in CTCL.
   Google Scholar
• Duvic M, Gather JC. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol. Clin. 18, 147–156 (2000).
   PubMedGoogle Scholar
• Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch. Dermatol. 134, 949–954 (1988).
   Google Scholar
• Herrmann JJ, Roenigk HH, Jr., Honigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hemata Oncol. Clin. N Am. 9, 1077–1088 (1995).
   PubMedGoogle Scholar
• Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hemata Onca Clin. N Am. 9, 1031–1055 (1995).
   PubMed Web of Science ®Google Scholar
• Bunn PA, Jr., Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Ann. Intern. Med. 121, 592–602 (1994).
   PubMed Web of Science ®Google Scholar
• Abel EA, Sendagorta E, Hoppe RT. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. Am. Acad. Dermata 14, 1029–1038 (1986).
   Google Scholar
• Piccino R, Caccialanza M, Mainardi L Comparison of the results obtained with ultraviolet radiation and photochemotherapy in the early stages of mycosis fungoides. Giornale Italiano di Dermatologia e Venereologia 125, 91–95 (1990).
   PubMedGoogle Scholar
• Hermann JJ, Roenigk HH, Jr., Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. jAm. Acad Dermata 33, 234–242 (1995).
   Google Scholar
• Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study. N Engl. J. Med. 336, 1041–1045 (1997).
   Google Scholar
• Rupoli S, Barulli S, Guiducci B et aZ Low dose interferon-a2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous T-cell lymphoma multicenter study group. Haematologica 84, 809–813 (1999).
   Google Scholar
• Stadler R, Otte HG, Luger T, Henz BM, Kuhl P, Zwingers T. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 92, 3578–3581 (1998).
   PubMed Web of Science ®Google Scholar
• •Randomized trial that establishes the high efficacy of the interferon and PUVA combination.
   Google Scholar
• Olsen E, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematot Oncol. Clin. N Am. 9, 1089–1107 (1995).
   PubMed Web of Science ®Google Scholar
• Thomsen K, Hammar H, Molin L et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaue stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm. Venereal. 69, 536–538 (1989).
   PubMed Web of Science ®Google Scholar
• jumbou 0, N'guyen JM, Tessier MH, Legoux B, Dreno B. Long-term follow-up in 51 pateints with mycosis fungoides and Sezary syndrome treated by interferon-a. Br. Dermatol. 140, 427–431 (1999).
   Google Scholar
• Steis RG, Smith JW, Urba WJ et al. Resistance to recombinant interferon a-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Engl. J Med. 318, 1409–1413 (1988).
   Google Scholar
• VanderMolen LA, Steis RG, Duffey PL, Foon KA, Smith JW, Clark JW Low-versus high-dose interferon a-2a in relapsed indolent non-Hodgkin's lymphoma. J. Natl Cancer Inst. 82, 235–238 (1990).
   Google Scholar
• Wolff JM, Zitelli JA, Rabin BS et al. Intralesional interferon in the treatment of early mycosis fungoides. J. Am. Acad. Dermata 13, 604–612 (1985).
   PubMed Web of Science ®Google Scholar
• Thestrup-Pederson K, Hammer R, Kaltoft K, Sogaard H, Zachariae H. Treatment of mycosis fungoides with recombinant interferon-a2a alone and in combination with etretinate. Br. J. Dermatol. 118, 811–818 (1988).
   Google Scholar
• Aviles A, Guzman R, Garcia EL, Diaz- Maqueo JC. Biological modifiers (etretinate and a 2a) in the treatment of refractory cutaneous T-cell lymphoma. Cancer Biotherapy Radio. 11, 21–24 (1996).
   Google Scholar
• Quesada JR, Talpaz M, Rios A et al. Clinical toxicity of interferons in cancer patients: a review." Clin. Oncol. 4, 234–243 (1986).
   Google Scholar
• Koh LK, Greenspan FS, Yeo PP. Interferon- a induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7, 891–896 (1997).
   PubMed Web of Science ®Google Scholar
• Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR Isotretinoin and cutaneous helper-T-cell lymphoma (mycosis fungoides). Arch. Dermatol. 123, 201–204 (1987).
   PubMed Web of Science ®Google Scholar
• Molin L, Thomsen K, Volden G et al. Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm. Venereal. 67, 179–182 (1987).
   PubMedGoogle Scholar
• Duvic M, Martin A, Kim Y et aZ Phase II and III clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol. 137(5), 581–593 (2001).
   PubMedGoogle Scholar
• •This article describes the multidose level trial demonstrating the effectiveness of bexarotene in refractory early-stage CTCL therapy and also details drug-related toxicities, such as central hypothyroidism and hypertrigylceridetnia and their management.
   Google Scholar
• Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational Phasetrial results. J. Clin. Oncol. 19(9), 2456–2471 (2001).
   Google Scholar
• •This article describes the multidose level trial demonstrating the effectiveness and toxicity of bexarotene in late-stage CTCL therapy, including potential efficacy in the treatment of tumor and erythrodermic-stage patients.
   Google Scholar
• Talpur RS, Ward S, Apisamthanarax N, Duvic M. Bexarotene combination therapy for cutaneous T-cell lymphoma. Society for Investigative Dermatology 62nd Annual Meeting. Washington D.C., USA, May (2001). (Abstract).
   Google Scholar
• Sherman SI, Gopal J, Haugen BR et aZ Central hypothyroidism associated wth retinoid X receptor-selective ligands. N EngLj Med. 340,1075–1079 (1999).
   PubMed Web of Science ®Google Scholar
• Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-een lymphoma. Hem. Onca Clin. 9,1057–1075 (1995).
   Google Scholar
• •A comprehensive overview of the Stanford, Hamilton and world data on total-skin electron beam therapy up until 1995.
   Google Scholar
• Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int.j Radiat. Oncol. 43, 951–958 (1999).
   Google Scholar
• Price NM, Hoppe RT, Deneau DG. Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer 52, 2214–2219 (1983).
   Google Scholar
• Duvic M, Apisarnthanarax N, Sung HG et aZ An analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. (in preparation).
   Google Scholar
• Quiros PA, Jones GW, Kacinski BM et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with Ti and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int.j Rad. Oncol. BioL Phys 38, 1027–1035 (1997).
   Google Scholar
• Licata AG, Wilson LD, Braverman, IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignanacies in cutaneous T-cell lymphoma: the influence of additional therapy after total skin electron beam radiation. Arch. Dermatol. 131,432–435 (1995).
   PubMed Web of Science ®Google Scholar
• Duvic M, Lemak NA, Redman JR et aZ Combined modality therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 34,1022–1029 (1996).
   PubMed Web of Science ®Google Scholar
• Diamandidou E, Colome-Grimme M, Fayad L, Duvic M, Kurzrock R Transformation of mycosis fungoides/ Sezary syndrome: clinical characteristics and prognosis. Blood 92,1150–1159 (1998).
   PubMed Web of Science ®Google Scholar
• Wilson LD, Licata Al, Braverman TM. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int. J. Rad. Onca BioL Phys 32,987–995 (1995).
   Google Scholar
• Olsen EA, Duvic M, Frankel et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19,376–388 (2001).
   PubMed Web of Science ®Google Scholar
• •A key trial on DAB389-1L2, the first genetically engineered CTCL cell-targeting drug to be FDA-approved; the article discusses response characteristics, pharmokinetics, drug safety profile and the differences between low and high dosing levels.
   Google Scholar
• Foss FM. DAB389IL-2 (ONTAK): A novel fusion toxin therapy for lymphoma. Clin. Lymphoma 1, 110–116, (2000).
   Google Scholar
• Duvic M, Gather J. Immunotoxin DAB389-interleukin-2 (Ontak) in the management of cutaneous T-cell lymphoma. Curr. Pract. Med. 2,7-9 (1999).
   Google Scholar
• LeMaistre CF, Saleh MN, Kuzel TM et aZ Phase I trial of a ligand fusion protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91, 399–405 (1998).
   PubMed Web of Science ®Google Scholar
• Duvic M, Gather J, Mazie J et at DAB389IL2 diptheria fusion toxin produces responses in tumor stage cutaneous T-cell lymphoma. Am. J. Hem. 58,87-90 (1998).
   Google Scholar
• Duvic M, Kuzel TM, Olsen E et al. Quality of life is significantly improved in CTCL pastients who responded to DAB389-1L2 (ONTAK) fusion protein (abstract). Blood 92(10 Suppl. 1), 624a (1998).
   Google Scholar
• Foss FM, Bacha P Kuzel TM. Biological correlates of acute hypersensitivity events with DAB389IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma 1, 298–302 (2001).
   Google Scholar
• Duvic M, Talpur R, Boh E, Sidique Y, Stevens V Improved tolerability of ONTAK (denileukin diftitox) with corticosteroid premedication patients with CTCL American Society of Hematology 43rd Annual Meeting. Orlando, USA, (2001). (Abstract)
   Google Scholar
• Fierro MT, Quaglino P, Savoia P, Verrone A, Bemengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP Leuk. Lymphoma 31,583–588 (1998).
   Google Scholar
• Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sezary syndrome. Hem. Oncol. Clin. 9,1109–1116 (1995).
   PubMed Web of Science ®Google Scholar
• Waddell CC, Zubler MA, Gore WS. Acute myeloblastic leukemia following chemotherapy for mycosis fungoides. Arch. Dermatol. 118,179–182 (1982).
   Google Scholar
• Kaye FJ, Bunn PA, Steinberg SM et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl. Med. 321, 1784–1790 (1989).
   PubMed Web of Science ®Google Scholar
• ••The only controlled, randomized trialdemonstrating that aggressive systemic chemotherapy does not improve overall survival in comparison to sequential conservative therapy.
   Google Scholar
• Vonderheid E, Bemengo MG, Burg G. Update on erythrodennic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J. Am. Acad. Dermatol. (In Press).
   Google Scholar
• Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl. Med. 316,297–303 (1987).
   PubMed Web of Science ®Google Scholar
• Heald PW, Rook A, Perez MI et at Treatment of erythrodermic cutaneous T-een lymphoma with extracorporeal photochemotherapy. Am. Acad. Dermatol. 27,427–433 (1992).
   PubMed Web of Science ®Google Scholar
• •Follow-up on the original Edelson et aL data demonstrating improved overall survival of CTCL patients with extracorporeal photopheresis therapy.
   Google Scholar
• Lim HW, Edelson RL. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematot Onca Clin. N Am. 9,1117–1126 (1995).
   PubMed Web of Science ®Google Scholar
• Di Renzo M, Rubegni P De Aloe G et al. Extracorporeal photochemotherapy restores Thl /Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology 92,99–103 (1997).
   Google Scholar
• Miracco C, Rubegni P De Aloe G et al. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study. Br. Dermatol. 137, 549–557 (1997).
   Google Scholar
• Jiang SB, Dietz SB, Kim M, Lim HW. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience. Photoderm. Photoimmunot Photomed. 15(5), 161–165 (1999).
   Google Scholar
• Fraser-Andrews E, Seed P, Whittaker S, Russell-Jones R Extracorporeal photopheresis in Sezary syndrome: No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch. Dermata 134, 1001–1005 (1998).
   Google Scholar
• •The trial that instigated a controversial debate on the efficacy of extracorporeal photopheresis in Sezary syndrome.
   Google Scholar
• Stevens S, Bowen G, Duvic M et al. Effectiveness of photopheresis in Sezary syndrome. Arch. Dermata 135, 995–997 (1999).
   PubMed Web of Science ®Google Scholar
• Edelson RL. Sezary syndrome, cutaneous T-cell lymphoma and extracorporeal photopheresis. Arch. Dermatol. 135, 600–601 (1999).
   PubMedGoogle Scholar
• Russell-Jones R Extracorporeal photopheresis in cutaneous T-cell lymphoma: Inconsistent data underline the need for randomized structures. Br. J. Dermatol. 142, 16–21 (2000).
   PubMedGoogle Scholar
• Duvic M, Hester JP, Lemak NA Photopheresis therapy for cutaneous T-cell lymphoma.' Am. Acad Dermata 35, 573–579 (1996).
   PubMed Web of Science ®Google Scholar
• Bisaccia E, Gonzalez J, Palangio Metal. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. J. Am. Acad. Dermata 43, 263–271 (2000).
   Google Scholar
• Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon-a: a 10-year experience at a single institution.' Am. Acad. Dermata 35(6), 946–957 (1996).
   Google Scholar
• Wilson LD, Jones GW, Kim D et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodennic (T4) mycosis fungoides." Am. Acad. Dermatol. 43, 54–60 (2000).
   Google Scholar
• Rook AH, Suchin KR, Kao DMF et al. Photopheresis: clinical applications and mechanism of action." Invest. Dermata Symp. Proc. 4, 85–90 (1999).
   Google Scholar
• Weinstein GD, Krueger GG, Lowe NJ et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy and duration of therapeutic effect. J. Am. Acad. Dermatol. 37(1), 85–92 (1997).
   Google Scholar
• Shalita AR, Chalker DK, Griffith RF et aZ Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 63(6), 349–354 (1999).
   PubMedGoogle Scholar
• Apisarnthanarax N, Talpur R, Ward S, Duvic M. Tazarotene 0.1% gel in the treatment of refractory mycosis fungoides: an open-label pilot study. American Academy of Dermatology Summer Meeting. Anaheim, USA, (2001). (Abstract).
   Google Scholar
• Fox E, Niu Z, Tobia A et al. Photoactivated hypericin is an antiproliferative agent that induces a high rate of apoptotic death of normal, transformed and malignant T-lymphocytes: implications for the treatment of lymphoproliferative and inflammatory disorders.' Invest. Dermatol. 111, 327–332 (1998).
   PubMed Web of Science ®Google Scholar
• Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.' Clin. Invest. 52, 1804–1811 (1973).
   Google Scholar
• Weinstein GD, McCullough JL, Olsen E Topical methotrexate therapy for psoriasis. Arch. Dermatol. 125, 227–230 (1989).
   PubMed Web of Science ®Google Scholar
• Clark C, Dawe RS, Evas AT et at Narrowband TL-01 Phototherapy for patch-stage mycosis fungoides. Arch. Dermatol. 136, 748–752 (2000).
   Google Scholar
• Coven T, Burack LH, Gilleaudeau P et al. Narrowband UV-B produces clinical and histological resolution of moderate to severe psoriasis in patients compared with broadband UV-B. Arch. Dermatol. 133, 1514–1522 (1997).
   PubMed Web of Science ®Google Scholar
• Lindsay KU A randomized, double-blind trial comparing pegylated interferon a-2b to interferon a-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395–403 (2001).
   PubMedGoogle Scholar
• Marolleau JP, Baccard M, Flageul B et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch. Dermatol. 131, 574–579 (1995).
   Google Scholar
• Baccard M, Marolleau JP, Rybojad M. Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2. Arch. Dermatol. 133, 656 (1997).
   Google Scholar
• Rook AH, Wood GS, Yoo EK et at Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotmdc T-cell responses. Blood 94, 902–908 (1999).
   PubMed Web of Science ®Google Scholar
• Duvic M, Phillips R, Yoon L et id Interleukin-12 therapy in early mycosis fungoides is associated with reduced expression of lesional cytokines. Society of Investigative Dermatology 62nd Annual Meeting. Chicago, USA, (2000). (Abstract).
   Google Scholar
• Zinzani PL, Baliva G, Magagnoli M et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.' Clin. Oncol. 18, 2603–2606 (2000).
   Google Scholar
• Foss FM. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. Semin. OncoZ 27(Suppl.), 58–63 (2000).
   Google Scholar
• Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.' Clin. Oncol. 17, 3117–3121 (1999).
   Google Scholar
• Foss FM, Ihde D, Breneman DL et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon a-2a in advanced mycosis fungoides/Sezary syndrome. J. Clin. Oncol. 10, 1907–1913 (1992).
   Google Scholar
• Margolis J, Greyer MR Pentostatin (Nipent): a review of potential toxicity and its management. Semin. Oncol. 27\(Suppl. 5), 9–14 (2000).
   Google Scholar
• Von Hoff D, Dahlberg S, Hartstock R et ed Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study." Natl Cancer Inst. 82, 1353–1355 (1990).
   Google Scholar
• Foss F, Ihde D, Linnoila IR et al. Phase II study of fludarabine phosphate and interferon a-2a in advanced mycosis fungoides/Sezary syndrome.' Clin. Onca 12, 2051-2059 (1994).
   Google Scholar
• Kuzel TM, Hurria A, Samuelson E et id Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87, 906–911 (1996).
   PubMed Web of Science ®Google Scholar
• Newlands ES, Blackledge GRP, Slack JA et aZ Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65, 287–291 (1992).
   Google Scholar
• Dolan ME, McRae BL, Ferries-Rowe E et aZ 06-Alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin. Cancer Res. 5, 2059–2064 (1999).
   Google Scholar
• Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52, 891–896 (1992).
   PubMed Web of Science ®Google Scholar
• Wollina U. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up.1 Cancer Res. Clin. Oncol. 127, 128–134 (2001).
   Google Scholar
• Prince HM, Seymour JF, Ryan G, McCormack C. Pegylated liposomal doxorubicin in the treatment of cutaneous T-cell lymphoma. jAm. Acad Dermata 44, (2001)
   Google Scholar
• Bunn PA, Jr., Norris DA. The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J. Invest. Dermatol. 95(Suppl.), 209S-12S (1990).
   Google Scholar
• Knox S, Hoppe RT, Maloney D et aZ Treatment of cutaneous T-cell lymphoma with chimeric antiCD4 monoclonal antibody. Blood 87, 893–899 (1996).
   PubMedGoogle Scholar
• Lundin J, Osterborg A, Brittinger Get al. CA/VIPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H Ttreatment in low-grade Non-Hodgkin's lymphoma. J. Clin. Oncol. 16, 3257–3263 (1998).
   Google Scholar
• Bigler RD, Gilley P, Micaily B et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant. 7, 133–137 (1991).
   PubMedGoogle Scholar
• Molina A, Nademanee A, Arber DA et al. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol. Blood Marr. Transpl. 5, 400–404 (1999).
   PubMedGoogle Scholar